Wire · founder news, decoded · opportunities
Merck gets FDA approval for first oral PCSK9 cholesterol pill
Merck received FDA approval for Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor for lowering LDL cholesterol, reducing it by up to 59% in trials and directly competing with injectable alternatives from Amgen, Regeneron, and Sanofi.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.
The Wire takeaway
If you build patient adherence software, data platforms, or digital therapeutics for chronic disease, Merck just handed injectables their exit date. The move from needle to daily pill reshapes the entire care workflow - and every incumbent injectable maker now needs to rebuild distribution, patient support, and pricing strategies for an oral world.
Read the full story at qz.com →
Topics: Digital Health · pcsk9-inhibitors · oral-formulation · cholesterol-treatment · market-displacement · fda-approval